Sotio

MaveriX Oncology is a biotechnology company dedicated to the discovery, development, and commercialization of targeted small-molecule cancer chemo-immunotherapies. The company focuses on innovative approaches that utilize previously unexploited insights into cancer and immune cell metabolism within the tumor microenvironment, which are applicable across various cancer types. By bridging the therapeutic gap in cancer treatment, MaveriX aims to enable medical practitioners to selectively deliver the tumor cell-killing effects of chemotherapy while simultaneously eliciting a robust immune response. This dual mechanism has the potential to enhance treatment efficacy against a wide range of cancers.

CytunePharma is a private company based in France that focuses on the research and development of novel immunotherapeutic agents, primarily targeting cancer. Founded in 2007, the company leverages a proprietary scientific breakthrough in immunology involving the trans-presentation mechanism of interleukin-15, a critical immune factor. Its lead compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector, enhancing the effectiveness of immune responses. CytunePharma is also working on conjugated monoclonal antibodies that are linked to CYP 0150, expanding its portfolio of therapeutic options. The company is managed by Dr. David Bechard, a seasoned biotech entrepreneur, and Dr. Yannick Jacques, who serves as the Director of Public Research at the French National Institute for Health and Medical Research.